Evaluation of prulifloxacin in the treatment of paranasal sinusitis

Abstract

After orally administering 200mg of prulifloxacin, the concentrations of UFX (an active metabolite of PUFX) in the paranasal sinus tissue ranged from 1.13 to 1.47μg/g at 70 to 120 minutes. The penetration ratios were 0.51 to 1.85 in the maxillary sinus mucosa, 1.46 to 2.63 in the ethmoidal sinus mucosa and 0.80 to 1.00 in the nasal polyp. The clinical efficacy rate at a daily dose of 200 to 600mg of PUFX was 84% (94% for acute sinusitis and 71% for an acute exacerbation of chronic sinusitis), while the radiological efficiency rate was 57%. The bacteriological eradication rates were 95% for gram-positive monomicrobial cases, 89%, for gram-negative cases and 100% for anaerobic monomicrobial cases. The rate for polymicrobial cases was 86%. Adverse reactions were observed in 2 cases (one case each of rash and diarrhea), and these symptoms disappeared during treatment (one case received a decreased dose). No abnormal changes were observed in the laboratory findings in any of the cases.